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Tuberculosis takes an enormous toll on
humankind. The impact of Mycobacte-
rium tuberculosis has not been weakened
despite the availability of effective anti-
tuberculosis agents. Industrialized coun-
tries recorded a net decline in the inci-
dence of tuberculosis during the 20th
century, but, unfortunately, developing
countries continue to witness the spread
of this disease at a frightening and in-
creasing pace. On the verge of the 21st
century, 18 million people globally were
newly infected with M. tuberculosis, 95%
of them in developing countries, and 2
million deaths resulted from uncon-
tained infections per year. Thus, tuber-
culosis remains a leading killer [1].
The key to the success of M. tuberculosis
is its unique ability to adapt to a wide
range of conditions, both inside and out-
side the human host [2]. Infection with
M. tuberculosis is most often acquired by
inhalation of small-particle droplets that
contain the bacterium. Once the pathogen
reaches the alveoli, it undergoes phago-
cytosis by alveolar macrophages. Some ba-
cilli may, however, resist destruction and
replicate within phagocytic cells. In re-
sponse, macrophages produce cytokines,
including TNF-a, IL-12, and multiple
chemokines. The latter act as chemoat-
tractants to recruit neutrophils, mono-
cytes, and lymphocytes. TNF-a and IL-12
facilitate IFN-g production by natural
killer cells and, subsequently, by T lym-
phocytes. Although these innate pulmo-
nary defense mechanisms limit the initial
replication and spread of invading my-
cobacteria, the extent of success varies
with the virulence and number of infect-
ing microorganisms. At this stage, all my-
cobacteria rarely are eliminated. Some in-
fected macrophages and dendritic cells
migrate to regional lymph nodes, where
the antigen-specific host response is ini-
tiated. It appears that gd T lymphocytes
are the predominant T cell population in
this phase of the immune response. They
produce a broad spectrum of cytokines,
including IFN-g, IL-2, IL-4, IL-5, and IL-
10, and can lyse infected macrophages. A
second wave of T cells (abT lymphocytes)
is attracted to and activated by the cyto-
kines produced by gd T lymphocytes.
These complementary T cell populations
produce cytokines and chemoattractants
that recruit uncommitted lymphocytes,
and the lymphocytes contribute in-
directly to mycobacterial elimination by
macrophage activation. Clones of M.
tuberculosis–reactive CD4 T cells are ex-
panded, some of which differentiate to
memory T lymphocytes. These cells me-
diate delayed-type hypersensitivity and,
together with M. tuberculosis–specific
CD8 T cells and CD1b-restricted T cells
that recognize mycobacterial lipids [3],
initiate the secondary immune response
displayed in lymphoid tissue, lung pa-
renchyma, and metastatic foci. IFN-g is
the key effector cytokine in control of
mycobacterial infection via macrophage
activation [4].
The efficacy of the secondary immune
response likely determines whether active
infection is terminated or progressive dis-
ease evolves. The most common outcome
of primary infection with M. tuberculosis,
however, is clinical latency, which repre-
sents a balance between the host’s cell-
mediated immune response and the ability
of mycobacteria to slow down replication
and wait patiently (dormancy). Currently,
2 billion people, 33% of the world’s pop-
ulation, are estimated to be infected with
M. tuberculosis, which provides an im-
mense reservoir for the pathogen, and 16
million of these subjects exhibit active
tuberculosis.
Latently infected persons represent a
potential danger. Impairment of cellular
immunity predisposes the host to reacti-
vation of latent infection and manifesta-
tion of disease. It is at this point that the
mycobacterial strategy of “winning by
waiting” pays off, because hosts with active
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infection are capable of transmitting M.
tuberculosis [2]. One dimension of the
danger attending latent infections has been
revealed by the ongoing HIV epidemic.
The dangerous liaison between HIV and
M. tuberculosis resulted in the resurgence
of tuberculosis in developed countries in
the late 1980s and early 1990s [5] and in
the unprecedented acceleration of the
spread of the disease in developing coun-
tries. Other factors impairing cellular im-
munity include malnutrition, use of im-
munosuppressive drugs, and senescence.
The only way to halt the spread of tu-
berculosis is to interrupt the chain of in-
fection. This requires that all infected per-
sons be identified and receive effective
antimicrobial treatment. A relatively sim-
ple diagnostic armamentarium suffices for
recognition of actively infected and highly
contagious persons, even in developing
countries. Acid-fast staining and micro-
scopic examination are sufficient to detect
the pathogen in the sputum of adults. Cul-
turing allows species identification and de-
termination of susceptibility to antimicro-
bial agents to be accomplished. On the
other hand, diagnosis of pulmonary tu-
berculosis is hampered if M. tuberculosis
organisms are not excreted in sputum in
numbers sufficient to be readily detected
by smear microscopy (∼104 cells/mL) or
if sputum cannot be obtained for micro-
biological investigation (e.g., from chil-
dren). Thus, for these patients, diagnosis
demands additional diagnostic tools, as
does the identification of latently infected
persons.
The tuberculin skin test (TST) repre-
sents such an additional tool [6]. It as-
sesses the degree of cellular immune re-
sponse to PPD of M. tuberculosis. In
sensitized persons, intradermally inocu-
lated PPD elicits induration at the injec-
tion site within 48–72 h. The size of the
induration depends on the number of in-
filtrating and accumulating cells during
this period of time. The majority of these
cells are memory CD4 T helper lympho-
cytes. In sensitized persons, they con-
stantly migrate in the bloodstream, snoop-
ing around for mycobacterial antigens.
However, the accuracy of the TST depends
on several factors. Most critical are errors
in placement and interpretation, which
can lead to either overestimation or un-
derestimation of sensitization. Contact
with environmental mycobacteria other
than M. tuberculosis, as well as previous
vaccination with BCG, may cause false-
positive results. Inherited or acquired im-
munodeficiency, iatrogenic immunosup-
pression, concomitant infections, and a
high mycobacterial load blunt intradermal
responses. Given the several drawbacks as-
sociated with the TST, more objective and
reliable tools for indirect detection of in-
fection with M. tuberculosis are highly
desirable.
Much attention has been devoted re-
cently to the IFN-g release assay (IGRA),
an in vitro assay marketed in Australia.
The assay is based on quantification of
IFN-g released by peripheral blood cells
after stimulation with PPD from M. tu-
berculosis and control antigens. Recently,
Mazurek et al. [7] reported the results of
a multicenter study that included 11200
adults in the United States and compared
the IGRA with the TST for detection of
latent M. tuberculosis infection. The au-
thors concluded that the IGRA and TST
were comparable in their ability to detect
latent tuberculosis. Unfortunately, this
conclusion was not supported by the re-
sults presented. Overall agreement be-
tween the IGRA and TST was 83%, and
agreement of the tests among persons at
risk for latent infection ranged from
89.9% to 92.7% for those with negative
results of the TST. However, agreement
was !65% for those with positive results
of the TST, regardless of whether the sub-
jects had been vaccinated with BCG. No-
tably, efforts to minimize the subjectivity
associated with reading TST results were,
apparently, not undertaken, because some
participating centers practiced digit pref-
erence (i.e., rounding measurements of
TST induration to the nearest multiple of
5 mm). The authors also favored the IGRA
because of its logistical advantage over the
TST in requiring a single patient visit.
However, this argument does not hold
true, because patients need to be told
about the results of the IGRA, and those
with latent tuberculosis need to have anti-
microbial treatment prescribed and to re-
ceive detailed information about it. There-
fore, a second visit would be required, at
least for those patients with latent tuber-
culosis. With the TST, the reading of the
results and treatment prescription are
done efficiently at the same visit.
In this issue of Clinical Infectious Dis-
eases, Bellete et al. [8] present an impor-
tant investigation of the IGRA’s perfor-
mance among 2 populations with different
backgrounds with regard to the prevalence
of tuberculosis. One population originated
from Baltimore and had varying levels of
risk of exposure to M. tuberculosis, and
the other consisted of subjects from
Addis Ababa, Ethiopia, where tubercu-
losis is highly endemic. Volunteers from
Baltimore had participated in the re-
ported US multicenter trial [7]. Two es-
sential issues were addressed. First, for the
IFN-g response, breakpoints other than
those recommended by the manufacturer
were examined. TST induration diameters
showed a bimodal distribution, but no
such modality was found for the IFN-g
responses. Thus, although the distribu-
tion of TST induration values allowed a
clear distinction to be made between pos-
itive and negative reactions, it was not
possible to designate a cutoff point for
the IGRA. Second, the reproducibility of
the IGRA results was assessed. Baltimore
subjects with discordant TST and IGRA
results were asked to participate in repeat
testing. Changes in TST results were
compatible with booster phenomena. By
contrast, changes in IGRA results were
random. Overall, the IGRA performed
with poorer sensitivity and specificity
than did the TST.
The IGRA is an attractive diagnostic
tool. However, studies assessing its per-
formance have not provided convincing
results. Before we can become excited
about the IGRA, various issues need to be
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resolved. The sensitivity and specificity of
the assay may be increased by use of more
apt and specific stimulatory antigens [6].
Reproducibility may be improved and in-
terpretation may be facilitated if host and
environmental factors that influence the
IGRA, including age, immune status, con-
comitant infections, and medications, are
clearly defined. IFN-g is a key component
of the host response to M. tuberculosis.
Nevertheless, immune reactions to this
bacterium are complex, and the spectrum
of immune responses, which also are in-
fluenced by the genetic background [9],
determines the outcome of M. tubercu-
losis infection. Indirect diagnosis of in-
fection with M. tuberculosis by assessment
of immune responses is, thus, prone to
error. Importantly, low IFN-g responses
must not be considered to exclude the
presence of infection. Risk-stratified in-
terpretation of TST induration takes this
into account. At this stage of develop-
ment and with current knowledge, the
IGRA can by no means replace the TST
for detection of active or latent infection
with M. tuberculosis.
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